SLS Stock News & Catalysts – SELLAS Life Sciences

FEATURED

SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026

− Company to present Phase 2 clinical data evaluating SLS009 (tambiciclib) in combination with azacitidine and venetoclax in patients who have previously failed venetoclax-based therapy − − Patients with

Summary

Nov 4, 2026, 9:00 AM ·Globe Newswire

RECENT

SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia

- Reaching the Pre-Specified 80th Event Triggers the Final Analysis of the Pivotal Phase 3 Trial - - Company to Report Topline Primary Endpoint Results this Quarter - NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) --

Oct 28, 2026, 8:35 AM ·Globe Newswire

SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer

SLS009 increased apoptosis more than six-fold versus daraxonrasib in a MYC-amplified, daraxonrasib-resistant patient-derived pancreatic cancer organoid model - Combination of SLS009 and daraxonrasib further increased

Sep 25, 2026, 1:00 PM ·Globe Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. ("Sellas" or the "Company") (NASDAQ:SLS). Such investors are

Sep 24, 2026, 5:34 PM ·PRNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. ("Sellas" or the "Company") (NASDAQ:SLS). Such investors

Sep 22, 2026, 8:12 PM ·Globe Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. ("Sellas" or the "Company") (NASDAQ:SLS). Such investors are

Sep 17, 2026, 10:00 AM ·PRNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. ("Sellas" or the "Company") (NASDAQ:SLS). Such investors are

Sep 3, 2026, 10:15 AM ·PRNewswire

SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer

- Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer – - Studies conducted in collaboration with the University of

Sep 2, 2026, 8:30 AM ·Globe Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. ("Sellas" or the "Company") (NASDAQ:SLS). Such investors

Sep 1, 2026, 6:23 PM ·Globe Newswire

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

- Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80th Event - - 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line

Aug 11, 2026, 4:05 PM ·Globe Newswire

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a

May 14, 2026, 8:00 AM ·Globe Newswire

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS

May 12, 2026, 4:05 PM ·Globe Newswire

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events – – First Patient Dosed in Phase 2 Trial of SLS009 in Newly

Mar 19, 2026, 4:05 PM ·Globe Newswire

SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for

Mar 17, 2026, 4:30 PM ·Globe Newswire

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

- Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS' Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilized -- Topline Data

Mar 12, 2026, 8:35 AM ·Globe Newswire

SELLAS Life Sciences Group, Inc. SLS · News